Abstract:Targeting AKT suppresses tumor growth through inducing apoptosis, however, during which whether other forms of cell death occurring is poorly understood. The effects of increasing PARP1 dependent cell death (parthanatos) induced by inhibiting AKT on cell proliferation were determined by CCK-8 assay, colony formation assay, Hoechst 33,258 staining and analysis of apoptotic cells by flow cytometry. For the detailed mechanisms during this process, Western blot analysis, qRT-PCR analysis, immunofluorescence and co-immunoprecipitation were performed. Moreover, the inhibition of tumor growth by inducing p53/SIRT6/PARP1-dependent parthanatos was further verified in the xenograft mouse model. For the first time, we identified that inhibiting AKT triggered parthanatos, a new form of regulated cell death, leading to colon cancer growth suppression. For the mechanism investigation, we found that after pharmacological or genetic AKT inhibition, p53 interacted with SIRT6 and PARP1 directly to activate it, and promoted the formation of PAR polymer. Subsequently, PAR polymer transported to outer membrane of mitochondria and resulted in AIF releasing and translocating to nucleus thus promoting cell death. While, blocking PARP1 activity significantly rescued colon cancer from death. Furthermore, p53 deletion or mutation eliminated PAR polymer formation, AIF translocation, and PARP1 dependent cell death, which was promoted by overexpression of SIRT6. Meanwhile, reactive oxygen species production was elevated after inhibition of AKT, which might also play a role in the occurrence of parthanatos. In addition, inhibiting AKT initiated protective autophagy simultaneously, which advanced tumor survival and growth. Our findings demonstrated that AKT inhibition induced p53-SIRT6-PARP1 complex formation and the activation of parthanatos, which can be recognized as a novel potential therapeutic strategy for cancer.

PARP1 Inhibitors Attenuate AKT Phosphorylation Via the Upregulation of PHLPP1

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction

Advances in using PARP inhibitors to treat cancer

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

Phosphorylation of Ribosomal Protein S6 Confers PARP Inhibitor Resistance in BRCA1-deficient Cancers

Differential Immunomodulatory Effect of PARP Inhibition in BRCA1 Deficient and Competent Tumor Cells

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.

Increasing radiosensitivity by the combined inhibition of PARP1 and PI3K in BRCA1-mutated triple negative breast cancer

An Update On Poly(Adp-Ribose)Polymerase-1 (Parp-1) Inhibitors: Opportunities And Challenges In Cancer Therapy

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

The role of PARP1 in the DNA damage response and its application in tumor therapy

Inhibition of AKT Induces P53/sirt6/parp1-Dependent Parthanatos to Suppress Tumor Growth

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Discovery, Mechanism and Metabolism Studies of 2,3-Difluorophenyl-linker-containing PARP1 Inhibitors with Enhanced in Vivo Efficacy for Cancer Therapy

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs